Amyris debuts Pathways Program: access to its synthetic biology technology.

January 17, 2016 |

In California, Amyris announced the availability of its Pathways Program, a program that provides partners a low-cost, low-risk opportunity to access Amyris’s industry-leading synthetic biology technology. Through the Pathways Program, partners can, with a small initial investment, sponsor and secure a molecule they are interested in having Amyris produce using the next-generation tools and technologies being developed through the company’s recently announced technology investment agreement with the Defense Advanced Research Projects Agency (DARPA).

In essence, this program opens up Amyris’s advanced technology platform and leading capabilities to researchers and companies wishing to determine the viability of biological production of target molecules at a lower cost and with minimized risk.

Amyris expects the powerful combination of its existing core technology and bioengineering advancements enabled by its project with DARPA will significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology. The Pathways Program allows partners to access these latest developments and explore bio-synthetic production opportunities with minimal risk and commitment.

The Pathways Program, Amyris says, provides partners with a de-risked opportunity to use Amyris’s expert capabilities and advanced tools and methodologies for the construction of organisms that convert sugar to the partner’s target molecule. The successful completion of the organism engineering potentially provides a new mode of production with secure stable supply from a renewable resource.

More on the story.

Print Friendly, PDF & Email


Category: Fuels

Thank you for visting the Digest.